Clinical Trials Browser

Withdrawn × liposomal doxorubicin × Clear all

NCT05295589 2023-09-26

Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy

Phase 2 Withdrawn

Platinum-Refractory Fallopian Tube Carcinoma

NCT03342300 2020-05-19

PDVPSTS

Phase 2/3 Withdrawn

Sarcoma

NCT02527772 2019-06-04

LD-FOX4/HCC

Phase 2/3 Withdrawn

Gastrointestinal

Carcinoma, Hepatocellular

NCT02557854 2019-03-19

HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid Tumors

Phase 1 Withdrawn

Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Desmoid Tumors

NCT03591744 2018-12-19

Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia

Phase 1 Withdrawn

Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell

NCT01490047 2015-06-16

Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas

Phase 1 Withdrawn

Lymphoma

NCT00706953 2015-04-06

A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With Bortezomib

Phase 2 Withdrawn

Multiple Myeloma, Recurrence

NCT00516191 2015-03-04

DMV

Phase 1/2 Withdrawn

Multiple Myeloma

NCT01281943 2013-07-04

Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer

Phase 2 Withdrawn

Gastrointestinal

Liver Neoplasms

NCT00434031 2012-07-30

CETRA

Phase 2 Withdrawn

Breast Neoplasms

NCT01333423 2012-06-26

Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)

Phase 1 Withdrawn

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT01492881 2012-05-11

Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma

Phase 2 Withdrawn

Multiple Myeloma

NCT00610792 2009-07-14

Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing Regimens

Phase 2 Withdrawn

Ovarian Neoplasms